SEARCH WITHIN CONTENT
VOLUME 15 , ISSUE 1 ( January-March, 2022 ) > List of Articles
Panneerselvam Rajaveni, Poongodi Venkatesan
Keywords : Nasal spray, Ryaltris, Seasonal allergic rhinitis
Citation Information : Rajaveni P, Venkatesan P. Drug Profile: Ryaltris Nasal Spray. 2022; 15 (1):19-21.
License: CC BY-NC 4.0
Published Online: 13-06-2022
Copyright Statement: Copyright © 2022; The Author(s).
Ryaltris is a metered, fixed-dose, prescribing nasal spray that delivers 665 µg of olopatadine hydrochloride, an antihistamine, and 25 µg of mometasone furoate monohydrate, a corticosteroid, in each spray. Ryaltris (olopatadine hydrochloride, mometasone furoate monohydrate) nasal spray has been approved by the Food and Drug Administration (FDA) for patients with 12 years and above for the treatment of symptoms associated with seasonal allergic rhinitis seasonal allergic rhinitis (SAR).